[Clinical trials of combination chemotherapy using cis-platinum with aclarubicin in intracranial rhabdomyosarcoma].
Combination chemotherapy of Cis-platinum with Aclarubicin was performed in patients with intracranial alveolar rhabdomyosarcoma. These patients were treated with Cis-platinum (20 mg/day) and Aclarubicin (20 mg/day) for 5 days. After two trials with about a four-week interval, complete tumor regression on CT scan was observed. Mild gastrointestinal toxicity was observed in these patients but the symptoms were transient and soon disappeared. No other side effects appeared, on or after treatment. This result demonstrated that combination chemotherapy of Cis-platinum and Aclarubicin is an effective regimen for remission induction chemotherapy in patients with intracranial sarcoma.
Wakabayashi
T
T
Yoshida
J
J
Ishiyama
J
J
Kageyama
N
N
D015250:Aclarubicin; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D009279:Naphthacenes / Q000008:administration & dosage; D012208:Rhabdomyosarcoma / Q000188:drug therapy* / Q000532:radiotherapy
D009279:Naphthacenes; D015250:Aclarubicin; D002945:Cisplatin